Insight

Yüksel Ürün: Cancer screening with multicancer detection tests

Photo taken from www.hraradiology.com

Jul 7, 2024, 10:43

Yüksel Ürün: Cancer screening with multicancer detection tests

Yüksel Ürün shared a post on X:

“Multicancer Detection (MCD) tests use one blood sample to screen for multiple cancers.

Potentially improves early detection, especially for cancers without effective screening.
Benefits and harms are still unknown.
Unlike conventional tests, the specific cancer organ is unknown, requiring broad diagnostics.
In studies with 16,000+ participants, MCD identified early-stage cancers like pancreas, ovary, liver, and more.
Sensitivity ranges from 27%-95%, lower for early-stage cancers.
False negatives may reduce standard screening adherence.
Trials needed to confirm accuracy, early detection effectiveness, and impact on overdiagnosis.”

Yüksel Ürün

Additional information.
Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

Ankara University School of Medicine cancer cancer organ cancer screening early-stage cancers Multicancer Detection (MCD) OncoDaily Oncology Yüksel Ürün

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage